Trial intelligence / Profile preview

Azilsartan vs olmesartan for mild to moderate primary hypertension

CTR20150586Phase 2Completed

Sponsor
Nanjing Huawei Pharmaceutical Technology Development
Start
Aug 2015
Modality
Small Molecules
Countries
1
01

Overview

A Phase 2 trial of azilsartan in essential hypertension, sponsored by Nanjing Huawei Pharmaceutical Technology Development. Started Aug 2015; status: completed.

02

Drugs

azilsartan
03

Conditions

essential hypertension

Beyond the preview

Go deeper on CTR20150586.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on CTR20150586.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call